Cargando…
Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis
Despite multiple possible oncogenic mutations in the proto-oncogene KRAS, unique subsets of these mutations are detected in different cancer types. As KRAS mutations occur early, if not being the initiating event, these mutational biases are ostensibly a product of how normal cells respond to the en...
Autores principales: | Le Roux, Özgün, Pershing, Nicole LK, Kaltenbrun, Erin, Newman, Nicole J, Everitt, Jeffrey I, Baldelli, Elisa, Pierobon, Mariaelena, Petricoin, Emanuel F, Counter, Christopher M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451540/ https://www.ncbi.nlm.nih.gov/pubmed/36069770 http://dx.doi.org/10.7554/eLife.75715 |
Ejemplares similares
-
Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach
por: Baldelli, Elisa, et al.
Publicado: (2022) -
Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer
por: Pershing, Nicole L.K., et al.
Publicado: (2016) -
Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021) -
CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
por: Klomp, Jennifer E., et al.
Publicado: (2021) -
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015)